Abstract
Background Substance use disorders (SUDs) remain common worldwide and inadequately treated. Neuromodulation targets neural circuits involved in reward, craving, and cognitive control. However, the primary research literature has not been systematically mapped regarding the relative contributions of clinical and preclinical studies.
Methods We conducted a multi-database bibliometric analysis of primary studies on neuromodulation for SUD. Web of Science, Scopus, and PubMed were searched covering 2000– 2025. After scope classification and exclusion of secondary literature, 810 primary research documents remained. Performance analysis and science mapping were performed with bibliometrix and VOSviewer.
Results Scientific output grew at a compound annual growth rate of 14.16% (2001–2025), accelerating after 2015. Of 810 studies, 82.8% were clinical, 12.5% preclinical, and 4.7% mixed/translational. Alcohol (31.5%) and nicotine/tobacco (25.7%) dominated the literature and were overwhelmingly clinical (>92%), whereas cocaine and opioids retained larger preclinical shares (≈24–27%). Repetitive transcranial magnetic stimulation (rTMS) was the leading modality (31.6%), followed by deep brain stimulation (24.9%) and transcranial direct current stimulation (24.2%). Keyword co-occurrence revealed three clusters: a clinical neuromodulation core, a nicotine/tobacco axis, and a preclinical reward-circuitry module. The United States and China led in output.
Conclusions Neuromodulation research for SUD is expanding rapidly and is heavily skewed toward clinical investigations. A persistent clinical–preclinical asymmetry and limited explicitly translational work constitute structural features of the field. Greater integration between mechanistic and clinical research is needed to advance definitive trials.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Statements and Declarations:
Conflict of Interest: The authors declare no conflicts of interest.
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
